Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.

Proton Rahman Iain B McInnes Atul A Deodhar Larissa Valor-Méndez Phillip J Mease May ShawiDaniel J CuaJonathan P Sherlock Alexa P KollmeierXie L XuShihong ShengChristopher T Ritchlin Dennis G McGonagle

Published in: Clinical rheumatology (2024)

ClinicalTrials.gov ( https://clinicaltrials.gov ) NCT03158285; Registered: May 16, 2017. Key Points • At week 100, 65% and 76% of guselkumab-treated patients achieved enthesitis and dactylitis resolution (ER/DR). • Achieving ER was associated with achieving DR and vice versa through the end of study. • Achieving ER or DR was associated with durable and meaningful improvements in selected patient-reported outcomes.

Keyphrases

patient reported outcomes
editorial comment
estrogen receptor
endoplasmic reticulum
newly diagnosed
breast cancer cells
juvenile idiopathic arthritis
end stage renal disease
single molecule
clinical trial
randomized controlled trial
peritoneal dialysis
patient reported
double blind